Glenmark Generics Inc, the US subsidiary of Glenmark Generics, today said that the US Food and Drug Administration (USFDA) has given final approval for Rizatriptan Benzoate tablets, its generic version of Merck's Maxalt tablets.
The company has commenced shipping immediately after the approval, Glenmark said in a statement.
The approval is for the 5 mg and 10 mg of Rizatriptan.
According to IMS for the 12 month period ending September 2012, Rizatriptan Benzoate tablets achieved sales of $333 million.
Glenmark's current portfolio consists of 82 products and 46 ANDAs pending approval with the USFDA.
Glenmark stock was trading at Rs 539, 0.14% down from Tuesday's close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app